相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening
Kristjan Sigurdsson et al.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA (2009)
A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions
Susanne K. Kjaer et al.
CANCER PREVENTION RESEARCH (2009)
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection
Sven-Eric Olsson et al.
HUMAN VACCINES (2009)
Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine
Suzanne M. Garland et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years
Cosette M. Wheeler et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
Darron R. Brown et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
HPV Screening for Cervical Cancer in Rural India
Rengaswamy Sankaranarayanan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening
V. M. H. Coupe et al.
BRITISH JOURNAL OF CANCER (2008)
Impact of vaccination with Cervarix™ on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age
Diane M. Harper
GYNECOLOGIC ONCOLOGY (2008)
Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark
Susanne K. Kjaer et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection
Luisa L. Villa et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen et al.
LANCET (2007)
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine
Sven-Eric Olsson et al.
VACCINE (2007)
Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ:: a combined analysis of four randomised clinical trials
L. Villa et al.
LANCET (2007)
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials
Elmar A. Joura et al.
LANCET (2007)
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Suzanne M. Garland et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination
J. Dillner et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2007)
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents - A randomized controlled trial
Keith S. Reisinger et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2007)
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women
Stan L. Block et al.
PEDIATRICS (2006)
HPV type-distribution in women with and without cervical neoplastic diseases
Gary Clifford et al.
VACCINE (2006)
Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
DM Harper et al.
LANCET (2006)
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia - A Randomized controlled trial
C Mao et al.
OBSTETRICS AND GYNECOLOGY (2006)
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
LL Villa et al.
LANCET ONCOLOGY (2005)
The Bethesda System 2001: an update of new terminology for gynecologic cytology
MR Henry
CLINICS IN LABORATORY MEDICINE (2003)
Epidemiologic classification of human papillomavirus types associated with cervical cancer
N Muñoz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The theoretical population-level impact of a prophylactic human papilloma virus vaccine
JP Hughes et al.
EPIDEMIOLOGY (2002)
Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles
TJ Palker et al.
VACCINE (2001)
分享论文
